AIDS 2024
The HPTN showcased key data and valuable insights during the AIDS 2024 conference, including symposia and posters on the use and implementation of long-acting cabotegravir for pre-exposure prophylaxis (PrEP), the effectiveness of PrEP in different populations, and notable innovative strategies used in HIV prevention.
Download the HPTN Abstracts at AIDS 2024
For a complete list of activities, browse the conference program.
HPTN at AIDS 2024
The HPTN collaborated with the HIV Vaccine Trials Network to host a Networking Zone in the Global Village:
Help End HIV: Clinical Trials for HIV Prevention
July 22-26, 10:00 a.m. - 4:00 p.m. CEST
Booth #: HT06
Description
Advanced HIV Disease: Hiding in Plain Sight
July 23, 3:00 p.m. - 4:00 p.m. CEST
Room 14b/Channel 3
Performance characteristics of HIV RNA screening with long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) in the multicenter global HIV Prevention Trials Network 083 (HPTN 083) Study [Slides] – Raphael Landovitz
SY25 Use of long-acting injectable cabotegravir in pregnant and lactating people
July 25, 10:30 a.m. - 11:30 a.m. CEST
Room 13a/Channel 7
- Association between substance use and PrEP adherence among AGYW enrolled in an HIV prevention study (HPTN 082) in Southern Africa
- Pre-Exposure Prophylaxis product choice of participants in HPTN 083
- A community-academic partnership to empower Black MSM for economic development, advocacy, and HIV prevention research: HPTN 096
- Changes in sexual behavior among adolescent girls receiving long-acting injectable cabotegravir for HIV prevention: the HPTN 084-01 study
- What factors influence whether stigmatizing attitudes change over time? An analysis of HIV stigma attitudes and perceptions among community members participating in the HPTN 071 (PopART) trial
- HPTN 094: Engaging Key Community Stakeholders in Preparation for Mobile Clinics Providing Integrated Health Services (Medication for Opioid Use Disorder and HIV Treatment/Prevention Services) for People Who Inject Drugs (PWID)
- Understanding Parental Motivations and Decision-Making for Adolescent Girls’ Participation in the Long-Acting Cabotegravir (CAB-LA) Trial – Insights from HPTN 084-1
- First-in-human evaluation of the safety, pharmacokinetics, and neutralization activity of PGDM1400-LS, a V2 glycan-specific HIV-1 broadly neutralizing antibody, infused intravenously or subcutaneously in people without HIV-1 (HVTN140/HPTN101 Part A)
- A first-in-human phase 1 trial of PGT121.414.LS administered alone and in combination with VRC07-523LS: safety, tolerability, pharmacokinetics, and neutralization activity (HVTN 136/HPTN 092)
- Enhancing Inclusivity: Examining the Global Impact of Cultural Competency on Clinical Trial Recruitment in HPTN – 10 Year Update
- “Everyone should have access to it”: perspectives on PrEP product choice and implementation from MSM and TGW in an injectable PrEP trial
Upcoming Events
